News & Press Releases
SET Announcements
Notification convening date of the Public Presentation
Read the full announcement on the SET website ↗Progress Report on Events or Indications Affecting Internal Control System. (Revised)
Read the full announcement on the SET website ↗Financial Performance Quarter 3 (F45) (Reviewed)
Read the full announcement on the SET website ↗Management Discussion and Analysis Quarter 3 Ending 30 Sep 2026
Read the full announcement on the SET website ↗Progress Report on Events or Indications Affecting Internal Control System.
Read the full announcement on the SET website ↗Financial Statement Quarter 3/2026 (Reviewed)
Read the full announcement on the SET website ↗Clarification on the Revisions of the Financial Statements for the First Quarter of 2026 (Further Revised) and the Second Quarter of 2026 (Revised)
Read the full announcement on the SET website ↗Management Discussion and Analysis Quarter 1 Ending 31 Mar 2026 (Revised)-Revised Auditor's Report
DOD BIOTECH PUBLIC COMPANY LIMITED submitted a revised auditor's report for its Management Discussion and Analysis for the first quarter ending 31 March 2026. The revised report covers the company's performance for the period.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Financial Performance Quarter 1 (F45) (Reviewed)(Revised Auditor's Report)
DOD Biotech reported a loss of 21,874 thousand baht for the first quarter ending 31 March 2026, compared to a profit of 27,204 thousand baht in the same period last year. Loss per share was (0.049) baht, versus earnings per share of 0.06 baht. The auditor’s report contains a qualified opinion with an emphasis of matters.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Financial Statement Quarter 1/2026 (Reviewed) (Revised Auditor's Report))
Read the full announcement on the SET website ↗Management Discussion and Analysis Quarter 2 Ending 30 Jun 2026 (Revised)
DOD Biotech Public Company Limited reported its Management Discussion and Analysis for the second quarter ending June 30, 2026. The announcement has been revised.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗Financial Performance Quarter 2 (F45) (Reviewed) (Revised)
DOD Biotech reported a qualified opinion on its reviewed financial statements for the second quarter and six months ended June 30, 2026. Profit attributable to equity holders was 941 thousand baht for Q2 2026, compared to 9,582 thousand baht in the same period last year. For the six-month period, the company reported a loss of 20,933 thousand baht, versus a profit of 36,786 thousand baht in 2025. Earnings per share were 0.002 baht for Q2 and (0.046) baht for the six months.
Summarised automatically from the announcement filed with SET.
Read the full announcement on the SET website ↗